TOPRAK, S. K. Et Al. 2004. Both higher level of (bcr,abl) transcripts and high Hasford risk score are associated with cytogenetic response but absence of molecular remission during first line use of imatinib mesilate(IM): A finding not observed following use among interferon failures.. 46th Annual Meeting of the American-Society-of-Hematology , (California, United States Of America).

TOPRAK, S. K., Dalva, K., Mizrak, D., Arat, M., Ozcan, M., GÜRMAN, G., ... Ilhan, O.(2004). Both higher level of (bcr,abl) transcripts and high Hasford risk score are associated with cytogenetic response but absence of molecular remission during first line use of imatinib mesilate(IM): A finding not observed following use among interferon failures. . 46th Annual Meeting of the American-Society-of-Hematology, California, United States Of America

TOPRAK, SELAMİ Et Al. "Both higher level of (bcr,abl) transcripts and high Hasford risk score are associated with cytogenetic response but absence of molecular remission during first line use of imatinib mesilate(IM): A finding not observed following use among interferon failures.," 46th Annual Meeting of the American-Society-of-Hematology, California, United States Of America, 2004

TOPRAK, SELAMİ K. Et Al. "Both higher level of (bcr,abl) transcripts and high Hasford risk score are associated with cytogenetic response but absence of molecular remission during first line use of imatinib mesilate(IM): A finding not observed following use among interferon failures.." 46th Annual Meeting of the American-Society-of-Hematology , California, United States Of America, 2004

TOPRAK, S. K. Et Al. (2004) . "Both higher level of (bcr,abl) transcripts and high Hasford risk score are associated with cytogenetic response but absence of molecular remission during first line use of imatinib mesilate(IM): A finding not observed following use among interferon failures.." 46th Annual Meeting of the American-Society-of-Hematology , California, United States Of America.

@conferencepaper{conferencepaper, author={SELAMİ KOÇAK TOPRAK Et Al. }, title={Both higher level of (bcr,abl) transcripts and high Hasford risk score are associated with cytogenetic response but absence of molecular remission during first line use of imatinib mesilate(IM): A finding not observed following use among interferon failures.}, congress name={46th Annual Meeting of the American-Society-of-Hematology}, city={California}, country={United States Of America}, year={2004}}